Imunon, Inc. (IMNN)
NASDAQ: IMNN · IEX Real-Time Price · USD
1.305
+0.055 (4.40%)
Jul 22, 2024, 10:01 AM EDT - Market open
Imunon Employees
Imunon had 33 employees as of December 31, 2023. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$571,307
Market Cap
12.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ontrak | 104 |
Check-Cap | 85 |
RedHill Biopharma | 53 |
Calidi Biotherapeutics | 41 |
Vaccinex | 40 |
Aptose Biosciences | 36 |
Lumos Pharma | 33 |
Monopar Therapeutics | 10 |
IMNN News
- 4 weeks ago - IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial - GlobeNewsWire
- 2 months ago - Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 2 months ago - IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study - GlobeNewsWire
- 2 months ago - IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO - GlobeNewsWire
- 2 months ago - IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 - GlobeNewsWire
- 3 months ago - IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 - GlobeNewsWire